军事知识服务平台
替加环素治疗呼吸机相关性肺炎老年危重症患者的疗效观察
Observation of the clinical efficacy of tigecycline for treatment of ventilator-associated pneumonia in critically ill elderly patients
摘要 目的:评价替加环素治疗呼吸机相关性肺炎(VAP)老年危重症患者的临床疗效。方法回顾性分析2011年6月至2014年3月浙江医院重症医学科应用替加环素治疗VAP老年危重症患者的病例资料,对其临床疗效进行评价。结果纳入79例患者(男83.5%),平均年龄84(65~100)岁。感染常见的致病菌为鲍曼不动杆菌(39.1%)、铜绿假单胞菌(35.0%)和肺炎克雷伯菌(23.8%)。所有患者均接受替加环素治疗,其中54.4%的患者联合其他抗菌药物,35.4%为加倍剂量应用,抗生素应用的平均时间为9(2~22) d。治疗结束后,临床成功44例(55.7%),临床失败29例(36.7%),临床不确定6例(7.6%)。治疗结束28 d后,患者总体病死率为39.0%。亚组分析表明,临床成功率与APACHEⅡ评分是否<15相关( APACHEⅡ<15与APACHEⅡ≥15的临床成功率分别为72.2%和41.9%,P=0.007),同时比较差异有统计学意义的包括替加环素是否使用加倍剂量(71.4%比47.1%,P=0.037),以及是否联合应用其他抗菌药物(67.4%比41.7%,P=0.022)。结论替加环素治疗VAP的老年危重症患者联合用药或使用加倍剂量均可改善临床疗效。
Abstract:
Objective To evaluate the efficacy of tigecycline for treatment of ventilator-associated pneumonia in critically ill elderly patients.Methods Data of critically ill elderly patients with ventilator-associated pneumonia treated with tigecycline in the intensive care unit was collected from June 2011 to March 2014 in this retrospective study, to evaluated the clinical efficacy of tigecycline.Results A total of 79 patients (83.5%male) were included, the mean age was 84 years old (rang, 65 years to 100 years old). Acinetobacter baumannii ( 39.1%) , Pseudomonas aeruginosa ( 35.0%) and Klebsiella pneumonia (23.8%) were the most common pathogens.All patients were treated with tigecycline, 54.4% combined with other antimicrobial agents, 35.4% treated with double dose of tigecycline, and the mean course of antibiotic treatment was 9 days (range, 2 days to 22 days).After treatment, clinical success were recorded in 44 patients (55.7%), clinical failure were recorded in 29 patients, clinical uncertainty were recorded in 6 patients.28 days after treatment, patients′overall mortality was 39.0%.The clinical success rates were associated with acute physiology and chronic health evaluation ( APACHE ) Ⅱ score less than 15 ( the clinical success rates were 72.2% and 41.9% in patients with APACHE Ⅱ score<15 and APACHE Ⅱscore≥15, respectively; P=0.007); treated with double dose of tigecycline (71.4% vs 47.1%, P=0.037) or combination regimens were also had significant difference (67.4%vs 41.7%, P=0.022). Conclusions Treatment of tigecycline combined with other antimicrobial agents and double dose of tigecycline may both can improve clinical efficacy in critically ill elderly patients with ventilator-associated pneumonia.
Author: Lü Xiaochun Cai Guolong Xu Qianghong
作者单位: 浙江医院重症医学科, 杭州,310013
刊 名 中华医学杂志 ISTICPKU
年,卷(期): 2016, (7)
机标分类号: R5 R47
在线出版日期: 2016年4月14日
基金项目: (2011R50018-13):浙江省重点科技创新团队自主设计项目(2011ZZ001):浙江省中医药重点研究项目(2013KYB004):浙江省医药卫生科技计划研究项目(2011R50018-02):省重点科技创新团队研究项目(2011R50018-13):Fund programScience and Technology Innovation Team in Design Independently Major Projects of Zhejiang Province(2011ZZ001):Major Projects of Traditional Chinese Medicine of Zhejiang Province (2013KYB004):Science of Medicine and Health Planning Research Project of Zhejiang Province (2011R50018-02):Science and Technology Innovation Team Major Research Projects of Zhejiang Province ,